Disitamab vedotin is a targeted drug indicated for the treatment of specific HER2-expressing solid tumors (including gastric cancer, urothelial carcinoma, etc.). Its price is highly influenced by dosage specification, region, and medical insurance policies.
In China, the price per vial is approximately 868–1,157 USD; the exact cost is calculated based on the treatment regimen and the patient’s body weight. Details are explained below.
I. Factors Affecting the Price
Dosage Specification and Administration
The commonly used strength is 60 mg per vial. The dosage is determined by the patient’s body weight (e.g., 2.5 mg/kg) and treatment cycle. A single treatment may require 2–3 vials, with an average monthly cost of about 2,170–2,893 USD.
Medical Insurance Reimbursement
The drug has been covered by medical insurance in some provinces and cities, with a reimbursement rate of approximately 30%–70%. However, reimbursement is subject to strict indication restrictions, requiring patients to meet criteria such as HER2 positivity.
Regional Variations
Tender and procurement prices vary across provinces. Some cities offer additional reimbursement through supplementary medical schemes such as Huimin Insurance.
II. Financial Assistance & Recommendations
Some medical institutions and pharmaceutical companies provide Patient Assistance Programs (PAPs). Eligible patients may apply for cost reductions or installment payments.
It is strongly recommended to obtain the drug through hospital pharmacies or authorized channels to avoid risks associated with unregulated sources.
III. Medication Guidance
Disitamab vedotin is a prescription drug. The dosage and treatment course must be strictly followed as directed by a physician; do not adjust or discontinue treatment without medical approval.
During treatment, regular monitoring of liver function, cardiac function, and blood routine is required. Seek immediate medical attention for severe allergic reactions, interstitial lung disease, or other serious adverse effects.
The exact cost and treatment plan should be confirmed by the attending physician after evaluating the patient’s condition. Patients are advised to discuss medical insurance coordination, treatment duration, and adverse event management during consultation.
